Do One Thing Every Day That Scares You
Venture partner Linda Bain recounts how a childhood performance panic sparked a lifelong habit of embracing uncomfortable choices, ultimately guiding her from a farming town to senior roles in big pharma and biotech. She argues that the biotech sector thrives on rapid, uncertain decisions, and that hesitation can cost time and market position. Bain illustrates this mindset through personal career pivots and a recent Kilimanjaro climb with industry peers, emphasizing that collective endurance drives success.
Balancing the Risks and Rewards of Drug Development in China: A Small Biotech CEO Perspective
The blog by HotSpot Therapeutics CEO Jonathan Montagu argues that China is no longer just a manufacturing hub but a burgeoning source of innovative drug candidates, evidenced by its 17% lead over the U.S. in Nature’s Index and nearly half...
Dual Wielding in I&I: A Pivotal Year Ahead
The article argues that the next breakthrough in immunology and inflammation (I&I) therapeutics will come from multi‑drug and multi‑target strategies rather than single‑target antibodies, which have hit an efficacy ceiling. It traces the evolution from early blockbuster biologics like Humira...
Why Owning the Learning Loop Matters More Than Owning the Lab
Nimbus Therapeutics, founded in 2009, has built a successful small‑molecule drug engine without owning any laboratories, relying on a Design‑Make‑Test‑Analyze (DMTA) learning loop executed through CRO partners. By keeping hypothesis generation, molecular design, data integration and decision‑making in‑house, the company...